JMIR Publications

ABSTRACT

Background:

Insulin resistance (IR) is a central factor in the pathogenesis and progression of metabolic disorders. Chinese herbal medicine (CHM) has been investigated as a potential therapy to enhance insulin sensitivity. A systematic review of the available evidence is needed to elucidate the potential effectiveness and harm of CHM for IR.

Objective:

Given the complexity of multi-herb formulas, this systematic review and meta-analysis focuses on single CHM to provide a clearer understanding of their individual efficacy and safety profiles.

Methods:

Various databases such as Cochrane Central Register of Controlled Trials, MEDLINE, Embase, Allied and Complementary Medicine Database, China National Knowledge Infrastructure, Chinese BioMedical Literature Database, Wanfang Database will be searched. Randomised controlled trials related to single CHM for treating adults diagnosed with IR-related diseases (e.g., T2DM, obesity) will be included. Two researchers will independently perform study selection, data extraction and quality assessment.

Results:

The primary outcome will be measurements that assess insulin resistance, such as hyperinsulinemic euglycemic clamp, homeostatic model assessment, and insulin sensitivity index. Secondary outcome will include adverse events. If feasible, a meta-analysis using RevMan V.5.4 software will be performed. Database searches will commence after the publication of this protocol, with an estimated commencement date of 1 November 2024.

Conclusions:

The findings of this study will provide valuable evidence to guide future research and promote evidence-based clinical practice. Clinical Trial: PROSPERO registration number: CRD42021285844.